<DOC>
	<DOCNO>NCT01923727</DOCNO>
	<brief_summary>This Phase I/IIa study evaluate safety feasibility [ 89Zr ] Df-IAB2M immunoPET tracer metastatic prostate cancer . Individuals participate study FDG PET scan , well four ( 4 ) PET scan ( 3 day period ) follow injection [ 89Zr ] Df-IAB2M PET tracer . Three different dose level explore . The purpose study demonstrate safety [ 89Zr ] Df-IAB2M , ability detect prostate cancer , optimal time point dose level imaging .</brief_summary>
	<brief_title>Phase I/IIA Study PET Imaging With 89Zr-Df-IAB2M Metastatic Prostate Cancer</brief_title>
	<detailed_description>IAB2M approximately 80 kDA molecular weight antibody fragment ( `` Minibody '' ) . Limited ( Phase 0/Proof-of-concept ) patient experience biologic target agent previously obtain SPECT image Ex-US , demonstrate target soft tissue bone lesion advance metastatic prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adult male &gt; /= 18 year age Patients histologically confirm prostate cancer Progressive disease manifest ( within 6 week screen ) either image modality ( bone scan , MRI CT ) OR biochemical progression ( PSA ) Performance status 60 high Karnofsky scale Subject 's schedule permit compliance study procedure Ability understand willingness sign write informed consent form Previous anaphylactic reaction huJ591 antibody FDG image On new anticancer therapy ( GnRH analog allow ) study Hepatic lab value : Bilirubin &gt; 1.5 ULN ; AST/ALT &gt; 2.5 ULN ; Albumin &lt; 2 g/dL ; GGT &gt; 2.5 ULN Alkaline Phostphatase &gt; 2.5 ULN Renal lab value : Creatinine &gt; 1.5 ULN Other severe acute chronic medical condition may increase risk associate study participation investigational product administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>[ 89Zr ] Df-IAB2M</keyword>
	<keyword>Prostate</keyword>
	<keyword>PET Scan</keyword>
</DOC>